Delivery Order SPE2DB20D2104-SPE2DB25FMYKE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $4,557.98. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count) with a ceiling value of $3,532.41. This competitive award, utilizing firm fixed-price terms, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Xifaxan 550 mg tablets in unit dose packaging (60 count) with a ceiling value of $1,625.31. This competitively awarded, firm fixed price delivery order is scheduled for completion by July 24, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $20,573.32. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is categorized as a child contract under AmerisourceBergen's broader federal contract portfolio. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed price contract valued at $4,888.67. This competitively awarded delivery order, with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) valued at $2,759.13. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents performance at the vendor's Conshohocken, Pennsylvania location. The award carries no set-aside designation, indicating it was competitively awarded through open competition. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) at a ceiling value of $1,846.22. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed price contract with a ceiling value of $24,364.10 and an ultimate completion date of July 22, 2025. This is a non-set-aside competitive award, with performance to be executed at the vendor's Conshohocken, Pennsylvania location. The delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $14,427.52 delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract structure. The award was made on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This contract represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $6,799.69. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through the DLA's open procurement process. The order is scheduled for completion by August 8, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMYKEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Xifaxan 550 mg tablets in quantities of 60 units, with a contract ceiling value of $1,640.75. This firm fixed-price delivery order, which is not set-aside, is scheduled for ultimate completion on August 21, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, which carries a $999,999,999.00 potential value through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, leverages its comprehensive IDC with the Defense Logistics Agency to deliver a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. This particular delivery order for Xifaxan, an antibiotic medication, exemplifies the company's role as a critical federal medical procurement vendor serving the Defense Health Agency and other government healthcare systems. As a competitively awarded, non-set-aside contract, this award reflects AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements within the agency's Medical Supply Chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 8/20/25 |